利拉鲁肽与二甲双胍对新诊断2型糖尿病患者骨代谢的影响

doi:10.3969/j.issn.1000-8535.2018.05.012

广州医药 ›› 2018, Vol. 49 ›› Issue (5): 48-51.DOI: 10.3969/j.issn.1000-8535.2018.05.012

利拉鲁肽与二甲双胍对新诊断2型糖尿病患者骨代谢的影响

张燕华, 唐奇志, 陈聪, 刘剑文

佛山市南海区中医院(广东省中西医结合医院)(佛山 528200)

收稿日期:2018-04-18 出版日期:2018-09-20 发布日期:2021-11-29
通讯作者: 张燕华,E-mail:2159363623@qq.com
基金资助:
佛山市卫生和计划生育局医学科研课题项目(20160231)

Effect of liraglutide and metformin on bone metabolism in newly diagnosed type 2 diabetic patients

ZHANG Yanhua, TANG Qizhi, CHEN Cong, LIU Jianwen

Traditional Chinese Medicine Hospital of Nanhai District of Foshan City (Traditional Chinese and Western Medicine Hospital of Guangdong Province), Foshan 528200, China

Received:2018-04-18 Online:2018-09-20 Published:2021-11-29

摘要/Abstract

摘要： 目的探讨利拉鲁肽与二甲双胍对新诊断2型糖尿病患者骨代谢的影响。方法选取2016年1月—2017年6月在我院就诊并确诊为新诊断2型糖尿病患者50例,按照随机数字表法将研究对象随机分为利拉鲁肽组及二甲双胍组,每组各25人。两组患者均单药治疗24周后比较两组患者骨密度、骨代谢指标变化情况。结果两组患者骨密度、血清ALP以及BGP、PINP水平治疗前后相比,无改变(P>0.05);而利拉鲁肽组患者的β-CTx水平较治疗前降低(P<0.05);两组患者治疗后FPG、2hFPG、HOMA-IR、HbA1c均较治疗前下降(P<0.05),而空腹胰岛素较治疗前上升(P<0.05);利拉鲁肽组患者治疗24周后BMI值低于治疗前(P<0.05)。结论利拉鲁肽与二甲双胍对新诊断2型糖尿病患者骨密度的影响均不明显,两种药物可有效降低血糖,改善胰岛素抵抗,利拉鲁肽在使用过程中可明显降低患者血清β-CTx水平,但其是否存在骨质保护作用仍需进一步研究。

关键词: 2型糖尿病, 利拉鲁肽, 二甲双胍, 骨代谢

Abstract: Objective To explore the effect of liraglutide and metformin on bone metabolism in newly diagnosed type 2 diabetic patients. Methods From January 2016 to June 2017, 50 patients with type 2 diabetes mellitus admitted to our hospital were selected. According to the random number table method, the subjects were randomly divided into liraglutide group and metformin group, 25 in each group. Changes in bone mineral density and bone metabolism were compared between the two groups after 24 weeks of monotherapy. Results That there was no significant change in bone mineral density, serum ALP, TPINP,and BGP levels before and after treatment (P>0.05). The β-CTx levels in patients in the liraglutide group were lower than that before treatment (P<0.05); FPG, 2hFPG, HOMA-IR, and HbA1c levels in the two groups were lower than that before treatment (P<0.05). Fasting insulin was higher than that before treatment (P<0.05); BMI was lower in the liraglutide group after 24 weeks of treatment than that before treatment (P<0.05). Conclusion The effects of liraglutide and metformin on the bone mineral density of patients with newly diagnosed type 2 diabetes are not obvious. Liraglutide may reduce serum β-CTx levels during use. We need to have further study whether it has a bone protection.

Key words: Type 2 diabetes, Liraglutide, Metformin, Bone metabolism

张燕华, 唐奇志, 陈聪, 刘剑文. 利拉鲁肽与二甲双胍对新诊断2型糖尿病患者骨代谢的影响[J]. 广州医药, 2018, 49(5): 48-51.

ZHANG Yanhua, TANG Qizhi, CHEN Cong, LIU Jianwen. Effect of liraglutide and metformin on bone metabolism in newly diagnosed type 2 diabetic patients[J]. Guangzhou Medical Journal, 2018, 49(5): 48-51.

参考文献

[1] CARNEVALE V, ROMAGNOLI E, D'ERASMO L,et al. Bone damage in type 2 diabetes mellitus[J]. Nutr Metab Cardiovasc Dis, 2014,24(11):1151-1157.
[2] OGATA M, IDE R, TAKIZAWA M, et al. Association between basal metabolic function and bone metabolism in postmenopausal women with type 2 diabetes[J]. Nutrition, 2015,31(11-12):1394-1401.
[3] 丁卓玲,熊杏安,肖硕.利拉鲁肽在2型糖尿病治疗中的应用进展[J]. 实用药物与临床,2014,17(5):615-619.
[4] 王覃,陈德才. 糖尿病对骨质疏松症的影响及其机制[J]. 中华糖尿病杂志, 2016,8(1):5-7.
[5] FORSLUND J M, ARCHDEACON M T. The pathobiology of diabetes mellitus in bone metabolism, fracture healing, and complications[J]. Am J Orthop,2015,44(10):453-457.
[6] HAMANN C, KIRSCHNER S, GÜNTHER K P, et al. Bone, sweet bone osteoporotic fractures in diabetes mellitus[J]. Nat Rev Endocrinol,2012,8(5):297-305.
[7] KARIM L, BOUXSEIN M L. Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties[J]. Bone,2016,82(1):21-27.
[8] GILBERT M P, PRATLEY R E. The impact of diabetes and diabetes medications on bone health[J]. Endocr Rev, 2015, 36(2):194-213.
[9] ZHEN D, CHEN Y, TANG X. Metformin reverses the deleterious effects of high glucose on osteoblast function[J]. J Diabetes Complications,2010,24(5):334-344.
[10] 赵辰荷,梁璟,杨吟秋,等. 胰高血糖素样肽-1对骨代谢的影响和潜在机制[J]. 复旦学报(医学版),2017,44(3):369-373.
[11] HU X K, YIN X H, ZHANG H Q,et al. Liraglutide attenuates the osteoblastic differentiation of MC3T3 E1 cells by modulating AMPK/mTOR signaling[J]. Mol Med Rep, 2016,14(4):3662-3668.
[12] KANAZAWA L,YAMAGUCHI T,YAMAMOTO M,et al. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus[J]. Bone Miner Metab,2010,28(5):554-560.
[13] 洪文婕,黄春仁,黄斌.二甲双胍和胰高糖素样多肽-1对2型糖尿病患者并发骨折恢复的影响[J]. 广州医药,2017,48(6):33-35,47.
[14] MABILLEAU G, MIECZKOWSKA A, CHAPPARD D. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials [J]. Diabetes,2014,6(3):260-266.
[15] SU B,SHENG H,ZANG M,et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment:a meta-analysis of randomized controlled trials [J]. Endocrine,2015,48(1):107-115.

利拉鲁肽与二甲双胍对新诊断2型糖尿病患者骨代谢的影响

Effect of liraglutide and metformin on bone metabolism in newly diagnosed type 2 diabetic patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	麦高阳, 李鲁强. 绝经前后女性2型糖尿病患者C肽水平与代谢综合征的关系[J]. 广州医药, 2021, 52(6): 76-79.
[2]	莫带弟, 罗笑卿, 赖文瑶. 二甲双胍用于治疗多囊卵巢综合征促排卵的疗效评价[J]. 广州医药, 2021, 52(6): 80-82.
[3]	骆超锋, 梁叠锋, 关国宏. 瑞格列奈联合胰岛素治疗2型糖尿病临床疗效及对患者血糖水平的影响[J]. 广州医药, 2021, 52(4): 65-67.
[4]	王曦龄, 李军, 李思源, 高群, 王双. 新疆绝经后女性2型糖尿病LRP5基因rs3736228、rs3781586位点的基因多态性及突变与糖、脂、骨代谢关系的研究[J]. 广州医药, 2021, 52(1): 6-11.
[5]	张浩航, 曾建红, 平丽, 李佩兰. 2型糖尿病男性患者血尿酸水平与骨质疏松及临床骨折的相关性研究[J]. 广州医药, 2020, 51(5): 46-49.
[6]	谭静. 基于互联网平台的健康管理模式对2型糖尿病患者血糖管理的效果[J]. 广州医药, 2020, 51(5): 111-114.
[7]	周扬, 陈菲, 马锋, 黄榕. 汉族、维吾尔族老年男性2型糖尿病合并骨质疏松患者25羟维生素D水平分析[J]. 广州医药, 2018, 49(4): 17-19.